Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 17/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2117588 | 0.95 | S1PR1 (0.49) | S1PR1S1PR3KCNH2XDH | |
| SCHEMBL2115561 | 0.89 | S1PR1 (0.53) | S1PR1S1PR3KCNH2XDH | |
| SCHEMBL2115754 | 0.88 | S1PR1 (0.50) | S1PR1S1PR3XDH | |
| SCHEMBL2123919 | 0.85 | S1PR1 (0.55) | S1PR1S1PR3KCNH2XDH | |
| SCHEMBL2122022 | 0.84 | S1PR1 (0.70) | S1PR1XDH | |
| SCHEMBL2124313 | 0.82 | S1PR1 (0.52) | S1PR1S1PR3KCNH2XDH | |
| SCHEMBL2132025 | 0.82 | S1PR1 (0.66) | S1PR1XDH | |
| SCHEMBL2116707 | 0.82 | S1PR1 (0.52) | S1PR1S1PR3 | |
| SCHEMBL2125227 | 0.81 | S1PR1 (0.72) | S1PR1XDH | |
| SCHEMBL2993433 | 0.80 | S1PR1 (0.65) | S1PR1S1PR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101083-A1 | S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120101083-A1 | S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120101083-A1 | S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120094979-A1 | THIAZOLE OR THIADIZALOE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO WELLCOME HOUSE (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20120094979-A1 | THIAZOLE OR THIADIZALOE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO WELLCOME HOUSE (GB) | 2012-04-19 | — | — | US | disclosed |
| US-20120094979-A1 | THIAZOLE OR THIADIZALOE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO WELLCOME HOUSE (GB) | 2012-04-19 | — | — | US | disclosed |
| WO-2010145202-A1 | THIAZOLE OR THIADIZALOE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010146105-A1 | S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094979-A1 | THIAZOLE OR THIADIZALOE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | S1PR1, S1PR5, S1PR2 | S1PR1 1/4885ESR2 1161/4885S1PR3 4/4885 |
| US-20120101083-A1 | S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885ESR2 443/4885S1PR3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.